Post navigation
- La metformina continua a sorprendere: nuove evidenze di riduzione del rischio postoperatorio
- Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial